Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

RSS Feed

Home
/
Brands
/
Glenmark Pharmaceuticals Inc., USA

Glenmark Pharmaceuticals Inc., USA Recalls

All product recalls associated with Glenmark Pharmaceuticals Inc., USA.

Get alerts for this brand

Recall Summary

Total Recalls

108

Past Year

Class I (Serious)

Most Recent

Nov 2025

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 101–108 of 108 recalls

Tacrolimus Ointment (Glenmark) – Packaging Defect (2022)

Defective Container: Tube split from side seam

Class IIILow

FDAJul 11, 2022Nationwide• Glenmark Pharmaceuticals Inc., USA

Aspirin Dipyridamole Capsules (Glenmark) – Capsule Breakage (2022)

Failed Tablet/Capsule Specification : Capsule breakage

Class IIILow

FDAJun 29, 2022Nationwide• Glenmark Pharmaceuticals Inc., USA

Ranitidine 300 mg Tablets (Glenmark) - NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class II

1...4 56

Page 6 of 6Next

Moderate

FDADec 17, 2019Nationwide• Glenmark Pharmaceuticals Inc., USA

Ranitidine 150 mg Tablets (Glenmark) - NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDADec 17, 2019Nationwide• Glenmark Pharmaceuticals Inc., USA

Ranitidine 300 mg Tablets (Glenmark) - NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDADec 17, 2019Nationwide• Glenmark Pharmaceuticals Inc., USA

Ranitidine 300 mg Tablets (Glenmark) - NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDADec 17, 2019Nationwide• Glenmark Pharmaceuticals Inc., USA

Ranitidine 150 mg Tablets (Glenmark) - NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDADec 17, 2019Nationwide• Glenmark Pharmaceuticals Inc., USA

Ranitidine 150 mg Tablets (Glenmark) - NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDADec 17, 2019Nationwide• Glenmark Pharmaceuticals Inc., USA